Patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC) research hub

Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020

This study is looking at a new medicine called ALECTINIB for people with a certain type of lung cancer (ALK+ Stage III NSCLC). We want to see how well it shrinks tumours before an operation and if it's safe to use. It's a Phase II study, meaning we're exploring its effects.